AstraZeneca Signs an Agreement with ArcherDX for Utilizing Personalized Cancer Assays to Detect MRD in Patients with Early-Stage Non-Small Cell Lung Cancer

Shots:

• AstraZeneca will utilize ArcherDX’s personalized assay in P-III MERMAID-1 study assessing the effect of adjuvant treatment with Imfinzi (durvalumab) + CT vs CT as monothx. in ~330 patients with resected (Stage II-III) NSCLC who have undergone complete resection of the primary tumor
• The 1EPs is DFS for patients showing MRD, which will be tested using personalized ctDNA assay based on whole-exome sequencing of patient samples.
• ArcherDX will perform whole-exome sequencing of samples of patients with NSCLC and generate personalized ctDNA assays to test MRD that remains after a patient’s surgery. The ongoing development of assays is informed by the TRACERx study, funded by Cancer Research UK and led by UCL and the Francis Crick Institute

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Yahoo Finance